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Abstract Two essential aspects of virtual screening are
considered: experimental design and performance metrics.
In the design of any retrospective virtual screen, choices
have to be made as to the purpose of the exercise. Is the goal
to compare methods? Is the interest in a particular type of
target or all targets? Are we simulating a ‘real-world’ set-
ting, or teasing out distinguishing features of a method?
What are the conﬁdence limits for the results? What should
be reported in a publication? In particular, what criteria
should be used to decide between different performance
metrics? Comparing the ﬁeld of molecular modeling to
other endeavors, such as medical statistics, criminology, or
computer hardware evaluation indicates some clear direc-
tions. Taken together these suggest the modeling ﬁeld has a
long way to go to provide effective assessment of its
approaches, either to itself or to a broader audience, but that
there are no technical reasons why progress cannot be made.
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Introduction
Virtual screening in the pharmaceutical industry is an
essential part of molecular modeling’s contribution to lead
discovery and, to a lesser extent, lead optimization. This has
led to considerable research into what method or approach
works best, typically by means of ‘retrospective’ evalua-
tions, i.e. attempting to predict future, i.e. prospective,
behavior by appraising techniques on known systems.
Despite this there is no agreed upon theory as to how to
conduct a retrospective evaluation. As a consequence, it is
very difﬁcult for an outsider to assess if methods are getting
better, have stayed the same, or even worsened over time. In
a practical enterprise, such as drug discovery, the proposed
beneﬁts of virtual screening, i.e. avoiding the cost and time
of a real screen, have to be weighed against one simple
question: does it actually work? Without proper metrics of
success, i.e. ones that go beyond the anecdotal, molecular
modeling is not guaranteed a vibrant future.
Observed as a general exercise, there are four elements
thatoughttobestandardforanypredictionstudy,whetherof
a virtual screen, or any general pattern recognition method.
The ﬁrst is whether the studyis well designed. The second is
what metrics are used to evaluate the outcome. The third is a
consideration of signiﬁcance, i.e. error analysis. And the
fourth is a reliable assessment of whether the results are
particularorgeneral.Allfouraspectsareimportantandyetit
is rare for a study in any ﬁeld to meet all these criteria. Even
in the most critical part of drug discovery, i.e. clinical trials,
there is considerable room for improvement, as several
recent retrospective studies of the medical literature have
demonstrated[1,2].Inreportsonvirtualscreening,infactin
molecular modeling in general, it is rare to ﬁnd an adequate
consideration of any of these issues.
Why is this? Why is the modeling ﬁeld so poor at the
most basic elements of evaluation? A charitable view would
be that, as with communication skills, most modelers
receive little appropriate formal training. Certainly there is
no central resource, whether scholastic review, book or
paper. A slightly less charitable view is that journals have
not developed standards for publication and as such there is
little Darwinian pressure to improve what the community
sees as acceptable. It is to be hoped that this is a learning
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required in a study. An extreme view is that we are poor at
evaluations because we simply do not matter very much. If
large fortunes were won or lost on the results from com-
putational techniques there would be immense debate as to
how to analyze and compare methods, on what we know
and exactly when we know it. There would be double blind,
prospective and rigorously reviewed studies of a scale and
depth unknown in our ﬁeld but common in, for instance,
clinical trials. In short, there would be standards.
In the hope that virtual screening is, in fact, worthwhile
we provide comment, suggestions and research on two
important aspects, namely experimental design and perfor-
mance metrics. Although the two are intimately linked, i.e.
an experiment should be designed with a mind to what is
being measured, there are distinguishable aspects. On
experimental design, extensive properties, such as number
of targets, actives and inactives, need to reﬂect a statistical
understanding of the current unreliability, or high variance,
of methods [3–5]. So dominant is this variance that it almost
renders moot any discussion of other matters, such as decoy
design. However, ultimately all aspects of design are
important. On decoy selection we suggest the necessity of
clarifying design intent and suggest four broad categoriza-
tions. In analyzing results, the issue of correlation is
considered. This often arises in the context of the 2D simi-
larityofactivesfromcongenericseries,butthe general issue
also concerns decoys, targets and methods. Research is
proposed that would clarify essential and poorly understood
issues, such as the transference of predictability between
closely related systems. On evaluation metrics we examine
the AUC (Area Under the Curve) of ROC (Receiver Oper-
ator Characteristic) curves [6–9]. Consideration of why the
AUC is a popular measure in many disciplines suggests
standards by which virtual screening metrics ought to be
judged. Finally, by evaluating average properties of large
numbers of systems, and by considering simple cost/beneﬁt
examples, we bring into question the validity and utility of
metrics proposed to capture ‘early’ behavior.
Experimental design
In what follows we consider the importance of both inten-
sive and extensive properties of an experiment. An
intensive property is something intrinsic to a design,
whereas extensive properties change with the size of the
system. For example, the type of decoys used in a retro-
spective study is an intensive property; the number of such
is an extensive property. We believe the most overlooked
intensive characteristic is the design goal, i.e. what is trying
to be proved. This typically falls into a few discrete classes
and appropriate labeling would help combine lessons from
different studies. For extensive quantities we consider how
common statistical approaches can aid the choice of num-
bers of actives, decoys and targets. Finally, actives, decoys,
targets or methods are not always independent and this has
to be quantiﬁed even in as simple a matter as comparing two
programs. Techniques for accounting for correlation within
an experimental design are known but rarely applied.
Intensive properties
One of the most basic issues in designing a retrospective
screen is how to chose decoys. Typically there are a certain
number of active compounds and one wishes to see if a
method can distinguish these from a second set, presumed
inactive. This is the most basic of classiﬁcation problems. Is
X of type A or type B? The legal system often has the same
dilemma, e.g. was X at the scene of a crime or not? A police
line-up has all the components of a virtual screen. Usually
the number of actives (suspects) is small, usually one. The
number of decoys (called ‘ﬁllers’) has to be sufﬁcient that
random selection does not compete with real recognition; a
minimum of four is usual. But it cannot be so large that guilt
is hidden within the statistical variance of the innocent. The
ﬁllers need to be convincing, i.e. not outlandishly dissimilar
to the guilty party, but not too similar or even potentially
also at the scene (i.e. false false positives). As courtroom
verdicts can depend on the appropriateness of a line-up,
standard procedures are well known.
We make the argument for four types of virtual
screening experiments; each with its own intent. Each of
the four designs ultimately consists of a random selection
of decoys but after the application of different ﬁlters.
(A) Universal. Any compound available to be physically
screened, typically either from vendors or corporate
collections.
(B) Drug-like. Available and drug-like, typically by
applying simple chemical ﬁlters.
(C) Mimetics. Available, drug-like and matched to known
ligands by simple physical properties.
(D) Modeled. Available, drug-like and derived using 3D
modeling on known ligands or the intended targets.
Although no classiﬁcation scheme could be perfect, fair
comparison of studies requires an alignment of intent. In
general, decoys get ‘harder’ from A to D, although this is
not necessarily true on a case-by-case basis and is itself an
interesting area of research.
The ﬁrst, and perhaps least in favor, is the universal
selection of decoys. A catalogue of compounds from a
vendor or set of vendors is treated as a general population
from which to draw. An example of a virtual study with
universal decoys can be found in Rognan et al. [10].
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esting intent. Faced with all compounds available for
testing, does a method distinguish known actives without
using prior knowledge of what makes a compound active?
Drug discovery has a long and successful history of grind-
ing up exotic plants and animals and screening for activity
and so this is a reasonable, if old-fashioned, approach. In the
Rognan set, for example, we ﬁnd I3, not likely to be a drug
but none-the-less an interesting molecule. The problem with
universal decoys is two fold. First, is it random enough?
The space of all possible chemistry is exceedingly vast
[11, 12]. The concept that a few thousand compounds, in
particular from a vendor database, could act as a thorough
sampling is implausible. In fact, there is now evidence
suggesting known chemistry is very restrictive [12].
Because of ‘inductive bias’, a concept frequently high-
lighted by Jain [13, 14], we tend to make what we know
might work, instead of sampling of what can be made.
Second, is it possible a universal decoy such as I3 might
stand out pretty much the same way a shady character
would stand out against a selection of school children, shop
clerks and nuns? Paul Hawkins has described this as the
‘dog’ test [15], i.e. if your dog could tell the difference
between the actives and inactives what have you really
proved? Actually, potentially a lot but only if the rest of the
experiment is designed with this choice of decoys in mind.
The problem here is one of dynamic range. If it is too easy
to distinguish an active then the only way to distinguish
between the methods is to test many, many times, i.e. to
improve the statistical power necessary to rank one method
above another. As is well known, and discussed below, the
error in any metric depends on both the number of actives
and the number of inactives. While it is trivial to increase
the number of (presumed) inactives almost without bound,
the number of actives is normally very ﬁnite. Only in some
of the more impressive published studies does the number
of actives exceed a hundred [3, 4] and it is this limitation
that really hinders random decoys being an effective
experimental design. We note that this is only a presumed
inadequacy of universal decoys; in fact such decoys may
prove difﬁcult for some computation methods, the Hawkins
dog test not with-standing. The point is that a presumed
limitation can be overcome by applying basic error analysis.
A more typical selection procedure is to choose from a
decoy set that is ‘drug-like’. Of course, there is no rigorous
deﬁnition of ‘drug-like’, but this does not stop it being
widely used. The intent is to mimic modern physical
screens and not test everything but instead be guided by
current dogma as to what a drug might look like. The most
prevalent of these descriptions is the famous Lipinski Rule-
of-Five, but there are many variants [16]. This is not dis-
similar to how police line-ups are actually constructed;
‘ﬁllers’ are normally acquired from local jails. In theory,
this should also be a harder test of methods because there
are less easily discernable inactives, although this is not
proven. Examples of this approach are the studies of
McGaughey et al. and Warren et al. One potential advan-
tage of this approach is that because decoys are derived
from characterized collections they are more likely to be
known to be inactives. This is typically only an assumption
for universal decoy sets. It is debatable as to how big a
problem false decoys are, but clearly they do not help.
There are also issues with drug-like decoys. Some com-
panies’ collections are heavily biased towards certain
targets that may or may not be related to the retrospective
study at hand. The study by McGaughey et al. reported
signiﬁcant differences in the efﬁciency of decoys chosen
from the MMDR, a kind of ‘consensus’ drug-like collec-
tion, compared to ones from their internal Merck database.
This trade of generality for local applicability is a char-
acteristic of many aspects of evaluations. For instance,
should targets be chosen to represent all possible systems, a
subset of pharmaceutical interest or a class within that
subset? What is gained in local applicability is often lost to
generality and prospective predictability.
The third approach is to ﬁnd mimetic or modeled decoys.
These are meant to stress-test methods and should be used
to compare approaches, rather than necessarily evaluate
real-world performance. Mimetic decoys are constructed so
that ‘simple’ methods cannot tell known ligands from
decoys. The rationale is utilitarian; why should one chose
to use sophisticated methods when simple, ligand-based,
ones can do just as well? Approaches include matching
physical properties, for instance size, number of hydrogen
bond donors and acceptors, lipophilicity, charge or ﬂexi-
bility [17]. An example of this approach is the DUD dataset
[18] of Irwin et al. Here, for each target thirty-six decoys
are found for each active by matching physical properties,
forming a mimetic set referred to as DUD-self. The com-
bined set, i.e. across all targets is drug-like and is referred
to as DUD-all. Mimetic decoys can sometimes be
depressingly effective, as illustrated by Irwin et al. How-
ever, in not all cases were DUD-self decoys harder to
distinguish than decoys from DUD-all. This at least sug-
gests physical property mimetics are not guaranteed to
provide a reality check for methods claiming to capture the
physics of drug-target interaction.
Modeled decoys go one step further than mimetics by
eschewing the concept of comparison to simple, practical,
methods and instead designing directly against the method
under study. As an example, suppose decoys for a docking
study were chosen such that every decoy had good shape
complementarity with some part of the active site, i.e. it ﬁt
well. It iswidely known that basic shape complementarity is
usually necessary for binding and forms a major component
of most scoring functions. Such a set of decoys would them
J Comput Aided Mol Des (2008) 22:239–255 241
123make fora challengingtestof scoring functions. But is this a
good test of docking? If essentially random performance is
seen an observer might decide docking is without merit,
whereas an appropriate conclusion would be that complex
scoring functions are useless. The inevitable desire of
methods to be seen to be useful often prevents modeled
decoys being chosen, even though they potentially address
the most interesting scientiﬁc questions. Irwin et al. had
intended their mimetic decoys to act more as modeled
decoys, i.e. the aim was to make things harder for docking
programs, but, as mentioned, this was not always achieved.
Although mimetic and modeled decoy selections have
virtues, they can also hamper comparison between different
studies. In the case of the mimetic approach, the deﬁnition of
‘simple’ evolves over time, especially as property calcula-
tions improve orchange. To arriveata set ofmodeled decoys
the procedure applied must be scrupulously described, e.g.
how is the protein prepared, how is the ligand protonated etc,
and complete and accurate descriptions of published virtual
screening procedures are rare. However, there seems no
reasonaconsensuscouldnotbereachedbyinterestedparties.
Standard protocols could be developed, shared and used to
verify results. The problems are more of will than ingenuity.
Given the above discussion, what is the appropriate
decoy set to use? A universal set with sufﬁcient actives to
enable discrimination between methods? A drug-like set
built from one group’s deﬁnition of a corporate collection,
but perhaps without general applicability? A mimetic set to
produce physically similar decoys? Or a modeled set
deﬁned so as to tease out speciﬁc differences between
methods, even at perception of poor performance? A sug-
gestion by Geoff Skillman [19] provides a novel
framework. Given the speed of modern computers and the
cost of storage and transmittal of information, there seems
no reason a retrospective study could not contain all decoy
types, with careful labeling of individual intent. The
authors can make of their data what they will, for instance
by reporting performance against a subset of decoys.
However, if a broader set is included in the supplementary
material, others can make use of the data for potentially
different purposes. One of the proposals of this paper is for
modeling to move beyond the anecdotal towards the sys-
tematic. Full reporting of data is essential but a further step
would be to include alternate data so that others can con-
struct purposes beyond the original intent.
Extensive properties
In addition to intensive properties, there are the extensive
properties such as how many actives, decoys and targets
are used. Once again the important consideration is
knowing what we want to know. If the purpose is to
evaluate a single method on a single target the necessary
extensive properties are quite different than for a broad
study on the efﬁcacy of several methods on many targets.
We illustrate this with some basic error analysis.
The Central Limit Theory (CLT) states that the average of
M measurements tends towards the true mean with an error
proportional to H(V/M), where V is the average squared
difference of a quantity from its estimated mean. Thus, the
error is an intrinsic quantity, the square root of V,d i v i d e db y
an extrinsic quantity, the square root of the number of mea-
surements. Famously, we have to take four times the number
of measurements to reduce the error by a factor of two. What
does this say as to the number of actives, decoys or targets
that should be used to accurately measure the performance of
a method? If the performance is similar no matter what
actives, decoys or targets are used then the variance is small
and M can be small. However, this is not the situation for
modeling techniques applied to real systems. Instead, it is the
ruling zeitgeist that ‘performance may vary’ [3–5].
Just how variable are virtual screening methods?
Figure 1a and b illustrate the extent of the problem by
presenting a reanalysis of the Warren et al. study from
GSK, with eight different docking methods and our own
work on the DUD dataset (DUD-self decoys) using four
different virtual screening techniques. The performance
metric is the AUC averaged over each dataset. The number
of targets for Warren et al. is eight and for DUD forty, i.e. a
Fig. 1 (a) Average AUC values across docking programs in the
Warren study, with 95% conﬁdence intervals. Where programs were
run in multiple modes the best average AUC was retained. (b)
Average AUC values plus error bars across the DUD dataset for four
in-house methods. Docking: FRED, Ligand-based: ROCS, 2D:
Lingos and MACCS Keys [20]. Also included for comparison
purposes is the average AUC for GOLD against the Warren set with
associated error bars
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conﬁdence limits at 95%, are slightly more than twice as big
for a method assessed against the GSK set than against
DUD. In addition it is clear that although methods in the
GSK test could be broadly classiﬁed as better or worse, this
is subject to considerable statistical dispute. The resolving
power of DUD begins to be apparent in Fig. 1b, where one
can begin to put some signiﬁcance to the generally held
belief that ligand-based methods perform better than
docking and about as equivalently as 2D methods [4, 21].
The average AUC and error bars for GOLD from the
Warren study are included in for comparison purposes only.
A more quantitative analysis of this data will be presented
below in the section on correlation between methods.
What is the source of so much variation such that even
forty targets are barely able to provide statistically sup-
portable conclusions? In general, given a property
measurement that has N independent sources of error, the
expected error is formed from the root mean square of the
individual sources of error, thus:
Err  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Err2
1 + Err2
2 + Err2
3 ...
   q
For our case we can write:
Err(method) 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(Err2
targets+Err2
actives+Err2
inactives)
q
 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(Vartargets/Nt+Varactives/Na+Varinactives/Ni)
q
The variances are intrinsic properties to ‘targets’,
‘actives’ and ‘inactives’. How do we know what these
variances are? One way is to boot-strap, i.e. leave out a
randomly chosen fraction of the targets, or subset of actives
or inactives, and measure changes in performance. Repeat-
ing this procedure many times gives a statistical sampling of
the sensitivity to outliers and the number of measurements.
Alternatively, in some cases the variance can be established
more precisely. In the case of AUC, for example, it can be
shown that for a particular target the variance for both
actives and inactives can be approximated by:
Varactive =
X
(pi  h pi)2/Nactive
Varactive =
X
(qj  h qi)2/Ninactive
where the sums are over all actives or inactives, pi is the
probability this active i has a higher score than an inactive,
qj is the probability an inactive j has a higher score than an
active and hi represents the average of a quantity [7].
Typically, the variances of both actives and inactives are
roughly equal. This leads to useful insights as to the
required ratio of decoys to actives. When this ratio is 100:1,
the net error is only larger by 0.5% than if we were to use
an inﬁnite number of decoys. A ratio of 40:1, roughly that
of the DUD-self set, yields an impact about 1%. At 10:1,
this impact is about 5% and at 4:1 about 11%. Note that
these effects on the error estimates, not on the actual
average. What does this look like in practice? Figure 2
shows the AUC values for FRED applied to DUD (self-
decoys), along with associated 95% conﬁdence intervals
for each system. Given these AUCs and contributions to
variance from actives and inactives, we can directly
address whether the source of the variance across targets is
due to insufﬁcient sampling of actives and decoys, or an
intrinsic property of methods. By the CLT,
Err(AUC)  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(VarObs/Nt)
p
where
VarObs =
X
(AUCi  h AUCi)2/Nt
Therefore
Vartargets =N t * f(VarObs/Nt)   (Varactives/Na)
  (Vardecoys/Ni)g
Table 1 shows contributions to the square of the average
error in the mean AUC across DUD for our four methods
Fig. 2 AUC values ordered from left to right by number of actives
for each target in the DUD set. Program used: FRED with Chemscore
as the posing and scoring function. Error bars are 95% conﬁdence
intervals for each virtual screen
Table 1 The contribution to observed variance from actives, decoys
and targets over the DUD dataset (DUD-self decoys)
Method hErr
2i -
Decoys
hErr
2i -
Actives
hErr
2i -
Observed
Est. hErr
2i -
Targets
FRED 0.000048 0.0020 0.023 0.021
ROCS 0.000025 0.0022 0.041 0.039
MACCS 0.00004 0.0017 0.030 0.028
LINGOS 0.000039 0.0017 0.035 0.033
The estimated error (squared) from the variation between targets is
estimated from the observed variance and corresponds to that which
would be obtained if the number of actives and inactives were inﬁnite
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from the inactives is about forty times less than that of the
actives (because the intrinsic variances are similar and there
are thirty-six times more decoys than actives in DUD-self).
Secondly, it is clear that the errors due to target variability is
roughly ten times higher than that due to actives. As inde-
pendent errors add as squares, this implies only about 5% of
the observed conﬁdence limit on the target-averaged AUC
is due to the ﬁnite number of actives. This leaves 95% of the
95% conﬁdence limit due entirely to the considerable var-
iation from target to target. Comparing DUD-self to the
careful evaluation of McGaughey et al. from Merck, and
Warren et al. from GSK, the latter have roughly four times
more actives and four times less systems, i.e. they are more
careful studies of particular systems (error bars are 50%
smaller per system) but substantially less useful for general
conclusions (error bars are twice as big per method).
Remarkably, even if the number of actives in each DUD-
self set were reduced by a factor of ten, causing a threefold
increase in the error estimation per target, the net error of
averages over all systems is only increased by about 30%.
The conclusions from this analysis of extensive prop-
erties are straightforward.
(1) When calculating the properties of a single system the
number of actives is fairly important, but the number
of inactives does not have to be substantially larger. A
ratio of decoys to actives of 4:1 only has an error 11%
higher than the limiting value from an inﬁnite number
of inactives. It would be more useful to include sets of
inactives designed for different purposes than to
attempt to ‘overwhelm’ the actives with decoys.
(2) If the purpose is to test a method against other
methods with 95% conﬁdence then the number of
systems required is very large, much larger than even
DUD. In our analysis the contributions to the variance
from a limited numbers of actives is almost insignif-
icant compared to the target-to-target variation. For
example, it would take over 100 test systems to tease
apart the difference between the ligand-based method
ROCS and the docking program FRED with 95%
conﬁdence. (See below.)
(3) The variance between systems is such that the number
of actives per target does not need to be very large,
perhapsevenaslowasten.Assuch,suggestionstoonly
include representatives of chemical classes, e.g. see
Good and Oprea [22], may be statistically quite valid.
Correlations
A key assumption underlying much statistical analysis is
the independence of samples, for instance that any two
measurements are uncorrelated. This is often a good
assumption but it is not hard to ﬁnd counterexamples.
Consider the case where a decoy is included twice. We
have gained no new information. Yet Ni, the number of
decoys, has increased and so the error goes down. Clearly
the error has not really been reduced. Instead, the decoys
are no longer independent. In the line-up analogy, this
would correspond to including identical twins as ﬁllers.
While this is an unlikely mistake, what about two indi-
viduals that look very similar? How independent are two
molecules and what does this even mean? The temptation
is to reach for the familiar chemical deﬁnition, i.e. 2D
similarity. Even though there is no rigorous deﬁnition of
chemical similarity, it is a major concern in selecting active
populations from chemically related (congeneric) series.
Methods that either rely on chemical similarity, or are
heavily inﬂuenced by it, may not be making independent
assessments. Clearly 2D methods fall into this category,
and sometimes ligand-based 3D methods. Ideally, methods
that use protein structure, such as docking, ought to be less
affected, but this is far from proven. Suggestions as to how
to improve matters include reducing the set of active to a
smaller set of representative structures [22], or giving more
weight to the ﬁrst compound discovered in a series [23].
(Application of similar protocols to decoys is seldom dis-
cussed, perhaps because they are less likely to be
congeneric). These are practical suggestions derived from
knowing the nature of drug discovery. There is also a
general approach that eschews the particulars. Two com-
pounds are considered operationally dependent if their
rankings under different tests are correlated. For instance, a
method that had a size-bias would tend to rank a pair of
molecules of comparable extent similarly, no matter what
the target. Even without 2D similarity, this implies a less
than perfect independence. Imagine a method where all the
decoys are of one size and all the actives another. No
matter what the actual number of actives and inactives,
there are essentially only two molecules, an active and an
inactive, and our ability to extract meaningful statistics is
severely compromised. Note that the operational part of
this deﬁnition depends on the nature of the method, i.e.
dependence is conditional on the nature of the procedure
investigated.
Similar situations occur in assessments of genetic link-
age. The degree of dependence amongst a set of markers is
evaluated by constructing a matrix where the entries are the
correlation of phenotypic scores between any two markers.
The eigenvalue spectrum of this matrix is then used to
assess the actual number of degrees of freedom [24].
Crucially, though, correlation can only be estimated by
knowing the behavior of a pair of samples/compounds over
many tests/targets. At ﬁrst glance this suggests that the
same set of decoys should be used across all targets in a
244 J Comput Aided Mol Des (2008) 22:239–255
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typically a part of the design, i.e. the decoy set is reused.
However, mimetic and modeled decoys rely on the nature
of the actives, which will vary from target to target. This
might seem a dilemma, i.e. we want to reuse decoys so we
know if they are correlated but we cannot reuse them
because one set of decoys may be completely inappropriate
for another target. Here Skillman’s suggestion is again
useful, i.e. there is nothing to stop us including the decoy
set for one target in the virtual screen of a second target not
as decoys but rather to gain information on operational
independence. To distinguish the role of decoys from one
system applied to a second system for purposes other than
assessing performance, we suggest the term ‘latent’ since
these secondary decoys should be hidden from the calcu-
lation of performance metrics. In addition to the concept of
latent decoys, latent actives can be used to measure oper-
ational independence independent of 2D similarity.
Another possibility is to use the actives from one system as
explicit decoys in other systems. For instance, in the
Warren et al. study each set of actives also formed the
decoy set for the other targets. The intent was just to
produce a set of drug-like decoys, but it fortuitously pro-
vides the most compact form for a rigorous estimation of
decoy/active independence. This work will be presented
elsewhere, along with an elaboration of the techniques for
assessing operational correlation.
We turn now to the question of target independence.
As we have seen, and is widely appreciated, the variation
of performance of methods from target to target is con-
siderable. But do certain targets, or classes of targets,
behave similarly for certain methods? For instance, one
would expect that a docking program parameterized
against certain binding motifs would perform similarly
across all targets with this motif, if only because of
inductive bias. Or one might assume that isoforms of a
target are sufﬁciently akin that docking methods would
perform similarly on each. Fortuitously, the Warren study
provides one such example in the inclusion of PDFE and
PDFS. Figure 3 shows the difference in performance of
methods used on isoforms versus the average difference
between all other pairs of targets. It is clear there is less
variance between the isoforms than unrelated targets. If
this were a generalizable result it would have two con-
sequences. On the positive it would mean that methods
could be quantiﬁed for certain types of problems without
requiring large numbers of targets, i.e. because the vari-
ance is smaller. On the negative, it would mean that just
as considerations need to be made for the true statistical
power of closely related actives, or inactives, similar
considerations need to be made for targets, increasing the
number of targets required to either discern general dif-
ferences between methods or to reliably gauge progress of
a single approach. And, as we have seen, to measure
global performance on independent systems already
requires sampling beyond common practice.
The PDFE/S example is a single data point. It is entirely
possible that the variation between targets of similar class,
or highly conserved isoforms, or even different forms of
the same protein structure is not small and that calculating
mean properties is still formidable. One might imagine this
is a well-researched area, but this appears not to be the
case. Retrospective experiments are designed, however
poorly, to give an estimate of to what to expect for the next
new target and so targets are chosen to be diverse. Software
would seldom be used in default, out-of-the-box, mode
when there is considerable domain knowledge, i.e. within a
set of closely related targets. Hence, the question of method
variance over similar systems appears to have been over-
looked.
The ﬁnal aspect of independence is correlation between
methods. Suppose we have method A and method B, each
tested on the same set of targets with the same set of
actives and decoys and the results show A is consistently
slightly better than B. How can we prove this difference is
statistically signiﬁcant? At ﬁrst glance this would seem
difﬁcult. As illustrated in Fig. 1a and b, the variance of any
one computational method over a set of targets in invari-
ably large. As such, the error bars on an average property,
such as an AUC or enrichment, are big. So although the
average behavior of method A is slightly better than B, this
difference would appear statistically insigniﬁcant. How-
ever, if the test systems are indeed identical this is not the
correct assessment. Instead, the CLT is applied to the set of
measured differences between methods, e.g. for an AUC
example the variance becomes:
Fig. 3 Docking performance against the two isoforms in the Warren
study (PDFS and PDFE), compared to the averaged difference over
all other pairs of targets
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The formula for Vardiff can be rewritten as:
Vardiff = VarA + VarB   2*Corr(A,B)
Corr(A,B) =
X
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Here Corr(A,B) is a measure of the correlation between
methods A and B and is related to the Pearson correlation
coefﬁcient, thus:
Pear(A,B) = Corr(A,B)/
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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If the tests of methods A and B are independent then the
correlation is typically assumed zero and the variance is
just the sum of the variances of both methods. If variances
were roughly equal, this would typically be a joint error bar
H2 larger than the individual error bars. (This also means
the common practice of evaluating whether two methods
are statistically different by whether their individual error
bars overlap is generally incorrect.)
However, if the tests applied to methods A and B are
identical, correlation needs to be explicitly included. In the
case of A always slightly better than B, we need to assess
whether the mean difference is larger than the joint conﬁ-
dence limits generated from the variance of the difference
between A and B. In fact, if A is better than B by a constant
amount we are guaranteed statistical signiﬁcance because
the variance of the difference is zero. In general, methods
tend to be positively correlated so that the joint conﬁdence
limits are lower than from independent measurements.
Conﬁdence limits are convenient because they give a
visual estimate of the possible range of true values, typi-
cally at a 95% level of conﬁdence. However, joint
conﬁdence limits are less graphical as they pertain to pairs
of methods. In addition, there is considerable concern in
other ﬁelds as to the arbitrariness of the 95% value. The
origin of this number is R. A. Fisher, whose work in the
1920s still dominates much of the ﬁeld of practical statis-
tics. Fisher, primarily an agriculturalist, observed a 10%
increase in cabbage yield when manure was used. He also
observed that only one in twenty plots without manure
showed a yield greater than 10%, and so the 95% cut-off
was born! From this, and because of the general utility of
Fisher’s work on experimental design, a p-value of 0.05
dominates many ﬁelds, in particular clinical trials. Essen-
tially, a p-value is the probability a null hypothesis can be
rejected. In our case the null hypothesis would be that
method B is in fact better than method A, despite average
values suggesting the reverse. Under the assumption the
difference in performance between two methods is as
predicted by the CLT (i.e. Gaussian), we can assign a
(p-)value to the probability one method is better only
because of random chance. We do this by calculating the
area under the normal form for which one appears better
than the other. The mathematics of this is shown below:
p =( 1  erf(hA   Bi*
p
(0.5*Nt/VardiffÞÞÞ/2
where hA–Bi is the average difference between the meth-
ods, the other variables are as deﬁned as above and erf is
the inverse cumulative Gaussian, or error, function. If Nt is
small, i.e. less than twenty, then a slightly different func-
tional form is more accurate (i.e. from the Student t-test)
because the CLT only applies in the limit of large N. For
practical purposes the difference can be ignored. The
smaller p, the stronger the case for A being better than B.
Note, we are not proving how much better A is than B. The
best estimate of A’s superiority is still the mean difference
of whatever property we are measuring. Rather the p-value
refers to the dichotomous question, is A better than B?
Table 2 illustrates the above concepts for the four
methods listed in Fig. 1b applied to DUD (DUD-self
decoys). The diagonal entries are the mean values of the
AUC of each method, followed by the associated 95%
conﬁdence limits. The upper triangle of the table contains
Table 2 Statistical measures necessary to accurately assess the relative performance of methods, here applied to the DUD data set (DUD-self
decoys)
Method FRED ROCS MACCS LINGOS
FRED 0.684/
0.043
0.11/0.08/
0.07
0.1/0.07/0.06 0.1/0.07/0.065
ROCS 0.17/0.09 0.732/0.065 0.12/0.085/
0.05
0.125/0.09/0.05
MACCS 0.03/0.05 0.70/0.47 0.734/0.055 0.115/0.08/
0.055
LINGOS 0.19/0.14 0.65/0.36 0.54/0.31 0.72/0.061
Diagonal terms: average AUC/95% conﬁdence limits. Upper triangle terms: naı ¨ve joint conﬁdence limits/joint conﬁdence limits assuming
different tests/joint conﬁdence limits assuming same tests and accounting for correlation. Lower triangle terms: Pearson correlation coefﬁcients/
p-values that a method has a higher mean AUC by random chance
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vidual conﬁdence limits, the joint conﬁdence limits
assuming independent tests and the joint conﬁdence limits
properly calculated with correlation. The lower diagonal
contains the Pearson correlation coefﬁcient for each pair of
methods, followed by the p-value for the hypothesis that
the better method is so only by chance. So, for example, the
probability that the 2D and ligand based methods are better
than the docking program FRED by chance are around
the 10% level, whereas the differences between these three
methods themselves is close to 50:50, i.e. in this example
we can distinguish ligand-based methods from a docking
protocol but not one ligand-based method from another.
This is most likely because DUD is not designed to test
ligand-based retrieval containing, as it does, many 2D
similar actives. Several others have made this point,
including the curators themselves [14, 18, 22]. Examples
from other ﬁelds of how to apply these procedures to dif-
ferences in AUC can be found in Hanley and McNeil [9].
One of the advantages of p-values is the statistical
machinery, again developed by Fisher [25], for combining
values from different studies. A classic example is the
effects of tobacco. It was not one study that convinced the
medical profession, but a series of studies and the facility
to combine the results that lead to the overwhelming con-
clusions as to the health risks of smoking. In statistics this
is referred to as ‘‘Meta-Analysis’’. Despite this, and the
wide application of p-values in other ﬁelds, they are largely
absent from modeling, with a few exceptions [5].
In conclusion, correlation is important in all aspects of
virtual screening, but perhaps most important and most
easily corrected for in the comparison of pairs of methods.
Neglecting the effects of correlation between tests is a
frequent problem even in clinical studies [2] and to our
knowledge has not been properly applied to comparing
methods in virtual screening.
Metrics
Given an experimental design, what quantities should be
measured to assess performance? The question suggests a
sequential process, i.e. design the experiment and then
measure something, whereas good design takes into
account what is going to be measured, in particular to what
accuracy. However, assuming a given design, how do we
extract useful information? In this section we consider
what should be measured and why. This is not a quandary
speciﬁc to virtual screening, in fact is it universal to all
prediction exercises. This very commonality can help
suggest worthwhile approaches. It also suggests that mea-
sures constructed speciﬁcally, even uniquely, for chemical
virtual screening should be held to a similar standard to
those prevalent in the wider world. Is virtual screening
really so different from, say, Internet page ranking? In
particular, we will consider the issue of ‘early’ behavior,
i.e. measures that reward ranking some active compounds
near the top of a list. By considering real-world ﬁnancial
parameters we ask whether ‘early’ behavior is even nec-
essarily to be prized. By looking at a large number of
virtual screens, we will ask whether such ‘early’ measures
are necessary and whether they can be predicted from more
fundamental and well-understood properties. Finally, the
application of accurate error bounds will be shown to
suggest at least one way of quantifying the advantage an
expert brings to well-studied systems.
Properties of virtual screening metrics
A long list of metrics has been applied to virtual screening.
What makes for a good metric? The unfortunate answer
with some papers is ‘‘any metric that will make my method
look good’’. And if no known metric will sufﬁce, then
simply make a one up. This is a typical indicator of an
under-regulated and under-developed ﬁeld. Computer
manufacturers used to habitually make up their own mea-
sures for the latest processor or operating system, leading
to much confusion and annoyance. As a consequence, in
1988 SPEC (Standard Performance Evaluation Corpora-
tion) was formed and SPEC Marks became the standard
benchmark of anything worth measuring. SPEC had a
simple philosophy: ‘‘The key realization was that an ounce
of honest data was worth more than a pound of marketing
hype’’ [26]. SPEC Marks have evolved over time to now
cover CPU, graphics, Java, mail servers, ﬁle servers, par-
allel performance, high performance computing and other
aspects. In other words, SPEC is not a single measure
because not all users want the same thing, but this does not
mean manufacturers can create their own metrics. Rather
SPEC is an umbrella organization for a set of open and
diverse groups that consider, ratify and develop bench-
marks. In this spirit, this section will concentrate on what
ought to be general characteristics of a good metric rather
than all prevalent quantities.
In a somewhat circular manner, one of the ﬁrst charac-
teristics of a good measure is that everyone uses it. Clearly
one of the problems with a ﬁeld with diverse measures is
incomparability, the ‘‘apples and oranges’’ problem. The
most straightforward solution is not imposition of a par-
ticular standard but full disclosure of all data. The authors
of a study may want to present enrichment at 5%, but if the
data is freely available others may calculate the enrichment
at 1% or 13% or whatever they wish. This would inevitably
lead to standardization as independent parties harvest data
from many sources, publishing larger and larger studies on
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measures. This would provide another example of meta-
analysis described above. Sometimes a valid excuse against
disclosure is that compounds or targets are proprietary.
However, just providing lists of actives and inactives in
rank order with unique, but not necessarily identifying, tags
is enough to calculate most of the metrics for a particular
virtual screen. Currently the ﬁeld of modeling lacks even
an agreed upon format for the exchange of such rarely
available information.
However, if we are going to report a statistic what
properties should it have? From considering measures that
have become standard in other ﬁelds, what characteristics
deﬁne a good measure? We suggest the following short
list:
(i) Independence to extensive variables
(ii) Robustness
(iii) Straightforward assessment of error bounds
(iv) No free parameters
(v) Easily understood and interpretable
Take for example the very popular ‘‘enrichment’’ mea-
sure. Everyone understands the concept of enrichment:
swirl a pan of water and gravel from the Klondike river in
1896 in just the right way and you ended up with mostly
gold. In virtual screening you look at the top few percent
and see whether there are more actives than you would
expect by chance. As a mathematical formula this is typi-
cally presented as:
EF(X%) = (100/X) * (Fraction of Actives Found)
The problem with this measure is that the enrichment
becomes smaller if fewer inactives are initially present.
Imagine panning for gold with all the sand removed. There
would still be the same gold in the pan, along with maybe
some pebbles and small rocks, but the eventual relative
improvement after ‘panning’, i.e. ‘enrichment’, is reduced.
The problem is that the (Fraction of Actives Found) con-
tradicts requirement (i), i.e. is a function of extensive
quantities, the number of actives and inactives. This means
that enrichment is not actually a measure of a method; it is
a measure of a method and a particular experiment. If the
ratio of inactives to actives becomes very large it is
assumed this problem disappears, i.e. that the limiting
behavior obeys (i). This is not true if the enrichment at a
given percent is large, i.e. at precisely the points of most
interest. Also, enrichment does not meet requirements (ii).
At a small enough percentage the enrichment becomes an
unstable function of the exact positions of actives in a list.
There is also no agreed upon percentage, making this an
adjustable parameter (often abused). Finally, other than by
bootstrapping, the author knows of no simple assessment of
error bounds. However, it is an intuitive measure, easily
understood, passing rule (v), and so almost uniquely to this
ﬁeld is the most common metric reported.
Some have been aware of the lack of robustness of
enrichment and proposed metrics that average over all
percentages with weighting schemes. Before we consider
these measures we point out that a simple ﬁx to the com-
mon variant of enrichment is to make the enrichment refer
to the fraction of inactives, not to the fraction of all com-
pounds. This simple change makes the enrichment
independent of extensive quantities, more robust, accessi-
ble to analytic error approximation [27] and yet suffers
only a slight reduction in interpretability. Only a few, such
as Jain [14] have used this alternate form. Perhaps the only
important failing of this measure is that it lacks a speciﬁc
name. For the purpose of this paper it will be referred to as
the ROC enrichment to distinguish it from the widely
abused variety.
ROC enrichment has better properties because is related
to an even better metric, the AUC, deﬁned as the area under
a ROC curve. A ROC curve is simply a plot of the dis-
covered active fraction versus the discovered inactive
fraction. (Each point on the ROC curve can be translated to
a ROC enrichment by dividing by the fraction of inactives).
The AUC is the average of this property over all inactive
fractions. Many excellent treatises can be found [6–9] and
it has become a standard for classiﬁcation performance in
many disciplines (medical diagnostics, radiology, clinical
testing, criminology, machine learning, data mining, psy-
chology and economics to name a few). It satisﬁes all of
the criteria listed above as a metric, including (v), ease of
interpretation. The AUC is simply the probability that a
randomly chosen active has a higher score than a randomly
chosen inactive. The main complaint against the AUC is
that is does not directly answer the questions some want
posed, i.e. the performance of a method in the top few
percent. This is akin to complaining that SPEC Marks do
not do a good job of evaluating mobile phone processors; a
fair complaint perhaps but hardly justifying creating a new
benchmark without the strengths of existing standards. The
AUC ought to at least be held as such a standard against
which new measures are judged.
Early performance in virtual screening
Figure 4 illustrates the supposed limitations of the AUC as
a measure of performance. The graph shows two ROC
curves, each with an AUC of exactly 0.5. Overall this
means that an active is as equally likely to out-rank an
inactive than the other way around. However, clearly in the
case of the solid line a certain fraction of actives is being
scored signiﬁcantly higher than most inactives, while
another fraction is being scored worse, i.e. it is only the
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dashed curve illustrates the case where the actives are all
scored better then a certain fraction of the inactives but
worse than another fraction. The solid and dashed curves
are instances of bimodal score distributions for the actives
and inactives respectively. Since the goal of a virtual
screen is to save us the trouble of actually screening all the
compounds it is entirely reasonable to prefer good ‘early’
behavior. And yet the AUC does not distinguish between
such curves and so, it is claimed, is not appropriate.
It is against this backdrop that metrics such as RIE [28]
and BedROC [29] were developed. In both cases the
essential idea is to give early rankings of actives more
weight than late rankings. In RIE/BedROC actives are
given a weight depending on their position in the list using
an exponential function running from 1.0 for the top ranked
compound to a number typically close to zero for the
lowest ranked. The exponential factor, beta, determines
how fast this exponential dies away from the top rank and
controls how much the RIE/BedROC parameter focuses on
the top of the list. The larger beta the greater the early
focus. In RIE the sum of active weights is normalized by
the RIE of a random distribution of actives. In BedROC
normalization is by the maximum dynamic range, i.e. the
score with all the actives ranked at the top minus the score
with all the actives ranked at the bottom. In addition, by
ﬁrst subtracting the score of the worst-case scenario,
BedROC has the elegant property of running from 0.0 to
1.0. The rational behind using these approaches is to give
precedence to actives ranking early but not to fall into the
trap of choosing a single enrichment value, i.e. be more
robust to perturbations in the rank ordering. Impressively,
Truchon and Bayly also derive analytic estimations of the
error bounds for BedROC and give some suggested values
for the beta parameter. Some incorrect statements regard-
ing the AUC mar their work, for instance that random
scores do not give an AUC of 0.5, and that the AUC is
dependent on the number of actives and inactives, but
overall the work is an interesting attempt to answer a
perceived need. Applied to the examples in Fig. 4, the ratio
of the BedROC score of the solid line to the dashed is about
two for a beta of ten and about ten for a beta of twenty.
So does BedROC or RIE qualify as a good metric for
virtual screening? Comparing against the ﬁve criteria listed
above, both are more robust than enrichment, and the error
protocols for BedROC satisﬁes criteria (iii). RIE suffers
from having an ill-deﬁned numerical interpretation (i.e.
how good is an RIE of 5.34?). BedROC attempts to
overcome this by scaling between 0.0 and 1.0, but does this
qualify as being understandable? There is no absolute,
interpretable meaning to a BedROC (or RIE) number, only
a relative meaning when ranking methods.
Unfortunately, neither BedROC nor RIE satisfy criteria
(i) or (iv), i.e. both are dependent on extrinsic variables and
have an adjustable parameter, the exponential factor beta.
The former, as we have seen, means that scores can only be
compared in the limiting case of an excess of inactives and,
as in the case of enrichment, this excess has to persist even
when the enrichment of actives is very high, i.e. it is
exactly when the actives are predominantly at the top of the
list that both BedROC and RIE (and enrichment) are most
sensitive to the total number of inactives. Interestingly, it
would be possible to reformulate both metrics to avoid this
problem. Just as ROC enrichment is a better metric than
enrichment, an exponential weighting across the ROC
curve, rather than to the individual rankings of actives
amongst inactives, would remove the sensitivity of these
measures to extensive properties. However, there would
still remains the issue of the arbitrariness of the exponential
factor beta. Just as with enrichment thresholds there is
nothing intrinsically wrong with the freedom to select a
threshold that is of interest to the particular research group.
Some companies might have the facility to physically
screen ten percent of their database, another only one
percent. However, as a characteristic of a method, or a
class of methods, it is a disadvantage. A proponent of a
method has a free parameter with which to make their
method look favorable or even just less unfavorable. In the
example in Fig. 4, a factor of two in BedROC between the
methods (beta = 5.0) does not sound anywhere near as bad
as a factor of ten (beta = 20.0).
Cost structures of virtual screening
There is no fundamental meaning to BedROC or RIE.
Neither gets to the real heart of why the solid curve in
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Fig. 4 Example ROC plots for ‘‘early’’ and ‘‘late’’ methods
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what follows we will argue that this can only be stated with
respect to a set of assigned costs, assumed but never stated.
We start by noting that the current focus on early enrich-
ment is actually a change in values for the industry. This
author recalls conversations in the mid-1990s wherein the
concept of missing any potential lead compound was
deemed unacceptable. By contrast, a preference for early
behavior implies it is acceptable to miss a signiﬁcant
fraction of potential actives in favor of ﬁnding a few good
leads. There is merit in this approach. Often a chemistry
team can only follow up on a small number of leads. High
throughput screens can take several months to design and
bring on-line, time chemists could use to explore initial
leads from a smaller focused set designed by a virtual
screen [30]. What are not made explicit in this shift are the
costs of the four components of any virtual screen: true
positives (TP), false negatives (FN), false positives (FP)
and true negatives (TN). Not wanting to miss anything is
equivalent to assigning an inﬁnite cost to a false negative.
This was never sensible, but reﬂected a ‘lottery’ mentality
prevalent at the time. The reality is that virtual screening
never ﬁnds drugs; at best it can ﬁnd things that might, after
considerable effort, become drugs. In addition, the attrition
rate at many stages in the drug design process means any
lead-like compound is at best a bet that will often fail,
costing many millions of dollars. A lottery ticket is
potentially worth millions; the expected value, i.e. aver-
aged over all contingencies, is usually less than the cost of
the ticket. The assumption behind virtual screening is that
the value of a true positive similarly averaged is worth the
cost of computers and modelers. This is an unproven
conjecture.
The assignment of a cost structure to the components of
a screen is common in the ﬁeld of medical diagnostics.
Here the costs can be estimated with some reliability. A
true positive represents the successful diagnosis of a con-
dition that will save money when treated. A false positive
means further, costly, tests will need to be performed. A
false negative might cost a lot if a more severe condition
develops. Finally, a true negative can be set to the cost of
the test or a small saving if compared to a more expensive
test. If these values are assigned to each ‘‘truth table’’
component (TP, FP, TN, FN), a ROC curve can be trans-
formed into a cost curve. A small caveat is that the ROC
curve deals with true and false positive rates and so to
transform to real costs the expected number of actives and
inactives is required, or at least the ratio of the two. Sup-
pose we apply a cost structure to Fig. 4 as follows:
(i) TP = 8.0
(ii) FN =- 2.0
(iii) FP =- 0.16
(iv) TN = 0.02
Positive numbers are favorable, for instance the cost
assigned to a true negative is the saving from not physically
screening a compound. At any point in the curve the cost of
progressing with all compounds higher than a given
threshold t depends on the False Positive Rate (FPR) and
True Positive Rare (TPR):
Cost(t) ¼ TPR*Na *(8.0) + (1   TPR)*Na *(  2.0)
þ FPR*Ni *(  0.16) +(1   FPR)*Ni *(0.02)
Let us assume Na/Ni = 1/100, then:
Cost(t)/Ni = (TPR*(8:0 þ 2:0Þ 2.0)/100
  FPR*(0.16 + 0.02) + 0.02
= 0.10*TPR   0.18*FPR
This is a simple linear scaling of the graphs in Fig. 4,a s
shown in Fig. 5a. As expected, the best approach is to take
the method with early performance over the later
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never cost effective and even the early method is only cost
effective for a narrow range of rankings.
Now consider a slightly difference weighting:
(i) TP = 8.0
(ii) FN =- 2.0
(iii) FP =- 0.04
(iv) TN = 0.03
Cost(t)/Ni =0.1*TPR   0.07*FPR + 0.01
Figure 5b illustrates the effect of these new weightings.
By reducing the cost of a false positive by 75%, i.e. to
around the savings of a true negative, both methods are
always cost effective. Furthermore, although the early
method has a clear maximum at around 20% of the data-
base, it is actually worth physically screening about 75% of
the database.
These examples are obviously only illustrative, but the
point they make is real. Early enrichment is important only
because of an assumed cost structure. Clearly much more
complicated models could be constructed, possibly with
real data, as with medical tests. However, to the author’s
knowledge this has never been published, presented or
even discussed within the industry. It is an assumption that
early enrichment is better. Likewise, it is also an assump-
tion that virtual screening itself is a productive exercise
compared to physical screening.
Averaged properties of virtual screening
Suppose the cost structure of virtual screening does favors
early enrichment. Can we at least say metrics such as RIE
and BedROC, perhaps reformulated to be independent of
Fig. 6 Averaged ROC curves
for twenty methods in the
Warren study for which scores
for all eight targets where
available. Programs and
scoring functions listed
to the right of the graph
Fig. 7 Average ROC curves for FRED, ROCS, MACCS keys and
LINGOS over DUD, with DUD-self decoys. FRED was run with the
ChemGauss3 scoring function
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123extensive variables, are superior to AUC? If the early
behavior shown in Fig. 4 were indeed repeated from system
to system then clearly this would be the case. In Fig. 6 we
show data from Warren et al. for twenty docking proce-
dures averaged over all eight targets in the study.
Examination of these curves reveals nothing that resembles
the biphasic nature anticipated from Fig. 4. Individual
curves might occasionally suggest biphasic behavior but
there is little evidence for this in target averaged ROC
curves. Figure 7 shows similar curves for the four methods
in Fig. 1b averaged across the DUD set. The curves in
Fig. 7 are smoother because the averaging across forty
targets in DUD is more extensive than the eight from GSK
and show even less evidence of biphasic behavior.There are
two possibilities for these observations. Either the
individual curves are not biphasic or the averaging dilutes
this characteristic. It is possible to imagine a technique that
would rank one type of actives well, perhaps hydrophobic
moieties, but ranks others badly, e.g. hydrophilic ones, but
that the proportions of each set differ target to target such
that the total behavior appears monophasic. To see if this
might be the case we examined two hundred and seventy
virtual screens from the Warren study, looking for a
divergence between BedROC, with exponential parameter
5.0, and AUC, i.e. an abnormally low AUC and a high
BedROC, although possibly the reverse. The results are
shown in Fig. 8. Clearly there is a strong correlation
between BedROC and AUC. Similar correlations were also
seen when higher exponential factors were employed and
suggest no evidence for biphasic behavior. A better AUC
Fig. 8 BedROC scores with an
exponential factor of 5.0 versus
the AUC for 270 virtual screens
from the Warren study
Fig. 9 The average AUC for
each method run against all
eight targets in the Warren study
versus the averaged BedROC
score for each such method
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123naturally leads to a better BedROC value and does so with
surprisingly little variation. It might still be possible that
one of the methods has average biphasic behavior, for
instance if all the BedROC/AUC points for a method
trended higher. Figure 9 shows this is not the case. Here, the
average AUC per method is compared to the average
BedROC value for that method. In addition, the correlation
is stronger the better the BedROC value, so that methods
that have a good AUC will also have a (strongly correlated)
good BedROC score.
There is one exception to monophasicity, shown circled
in Fig. 9. This point lies outside the 95% conﬁdence limits
of both AUC and BedROC. Its BedROC score is signiﬁ-
cantly higher than expected and its AUC is around 0.5, i.e.
random ranking. The target protein represented by this point
is PPAR-d and the method is MVP, a program developed in-
house at GSK by Mill Lambert. In conversation Lambert
freely admitted that not only did he have extensive
knowledge of this target, he used all of this information to
tune MVP. Unfortunately, because of certain aspects of the
target he could only select one of three chemical classes for
this ‘hands-on’ treatment at a cost to the two other classes.
Hence, MVP had to be biphasic. It seems interesting that out
of two hundred and seventy virtual screens the only outlier
from the BedROC-AUC correspondence is an example of
expert intervention. An unintended consequence of this
study might be a method to spot and quantify expert con-
tributions to virtual screening, i.e. by comparing early
behavior, either with BedROC or other metrics, to that
predicted from the fundamental measure of AUC.
Conclusions
In this study we have considered several aspects of
experimental design and performance metrics for virtual
screening. There is clearly interest in doing things the right
way, not least because of a popular, if unproven, belief that
virtual screening saves the pharmaceutical industry money.
As with many relatively young endeavors, molecular
modeling has been long on promises and short on stan-
dards, and it is standards that ultimately deliver the proof
that our ﬁeld is useful. For many years the computer
industry suffered from similar growing pains. Not only
were there few, if any, reliable comparison metrics for
different processors, operating systems, compilers and so
forth, the proposed beneﬁts of computers were more
assumed than quantiﬁed. These days no one doubts the
impact of the computing revolution. It is to be hoped that a
similar statement can one day be made for molecule
modeling. It is with this in mind that the following
observations and recommendations are made.
On the issue of experimental design we propose:
(i) Decoy selection needs to be properly labeled as to
intent to facilitate inter-study comparison. We have
suggested four classiﬁcations, universal, drug-like,
mimetic and modeled based on examples from the
literature and on typical use-case analysis.
(ii) Providing access to primary data would allow the
ﬁeld to gain cumulative knowledge. The ﬁeld of
modeling has almost no ‘‘meta-analysis’’, i.e.
research combining the results from studies, largely
because of a lack of standards as to procedures and
measures, but also due to the lack of primary data. A
comprehensive format for virtual screening informa-
tion would be useful.
(iii) The inclusion of multiple decoy sets of different
design and intent for each target in an evaluation
would, in combination with (i) and (ii) above, greatly
increase the cumulative value of published studies.
(iv) The number of targets, actives and inactives need to
be carefully considered with respect to the purpose of
the experiment and the required accuracy of the
results. These can be derived from simple statistical
methods that are almost never applied.
(v) The effects of correlation between actives or inactives
can be generally deﬁned as an operational quantity.
This could be investigated if actives and inactives for
one target were included as explicit or latent decoys
for all other targets. Warren et al. provides an
example of the ﬁrst, i.e. decoy sets were made from
the actives of other targets. The second is an
extension of point (iii), i.e. include multiple sets of
decoys in a study but for different purposes. In
conjunction with (ii) above, this would provide
material for a rigorous analysis of operational corre-
lation in virtual screening.
(vi) Correlation between targets needs further research, in
particular the question of the variance of computa-
tional methods on closely related systems.
(vii) Differences between methods, especially within a
single study over multiple targets, should only be
reported if the effects of correlation are included.
Editors of journals should never publish papers that
suggest one method is better than another if these
basic statistics are not employed. At a minimum it is
recommended that the method variances along with
correlation-corrected joint conﬁdence limits be
reported. This would allow the estimation of
p-values for any assessment of method superiority.
On the issue of performance metrics we propose:
(i) Deciding on the metrics to be reported should be a
community effort, although access to primary data to
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123encourage ‘‘meta-analysis’’ would aid the autonomous
adoption of metrics.
(ii) There are good reasons metrics such as the AUC are
popular in other ﬁelds and any new or additional
measures for virtual screening need to be assessed
against the characteristics that have made such
metrics successful. Five characteristics required for
a metric to be of similar heft to the AUC are
proposed: independence to extensive variables,
robustness, error bounds, no adjustable parameters
and ease of interpretation. As an illustration, an
improvement to the common enrichment measure is
described. We propose the term ‘‘ROC enrichment’’
for this new measure. Similar improvements to early
measures are proposed.
(iii) Currently, it would seem that providing AUCs and a
few ROC enrichment values for the early part of a
screen, e.g. 1% and 2%, would capture most average
behavior of interest.
(iv) The assumption that ‘early’ behavior is necessarily a
beneﬁt is based on an assumed cost structure that
may or may not hold. Similar statements are true for
virtual screening in general. A rigorous attempt to
assign real-word costs would be of use to the ﬁeld.
(v) We have found very little evidence that suggests
average behaviors cannot be accurately predicted by
AUC or obvious extensions there of. Those suggest-
ing otherwise need to provide clear-cut, statistically
valid, evidence.
(vi) Divergence from (v) may be an indicator of local or
domain knowledge, i.e. knowing the right answer
and/or extensive knowledge of the system under
study. A potential future area of research is whether
this is also an indicator of over-parameterization,
posterior system preparation or other reliance on
retrospective knowledge. Interestingly, 2D methods
applied to DUD, showed no evidence of such a
divergence.
Inconclusion,thereisnoreasonitisnotpossibletoestablish
standards in the ﬁeld of molecular modeling necessary to
enhance the quality of publications and allow a reliable
assessmentofmethodsandprogress.However,therearealso
powerful incentives not to be rigorous. As one invested
scientist was heard to pronounce, ‘‘livelihoods are at stake’’.
This is true; we suggest the livelihood of the entire ﬁeld.
Whether the modeling community has the will to enact such
measures may well determine whether future generations of
scientists look back and see a ﬁeld that became essential to
drug discovery or one that became a mere footnote.
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